COSCIENS Biopharma (CSCI) Appoints Anna Biehn as CEO Apr 14, 2025 07:02AM
COSCIENS Biopharma (CSCI) Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product Mar 13, 2025 07:58AM
COSCIENS Biopharma (CSCI) Provides Corporate Update and Highlights Pipeline Prioritization Dec 23, 2024 07:46AM
COSCIENS Biopharma (CSCI) Announces Resignation of Carolyn Egbert from Board Oct 8, 2024 07:31AM
COSCIENS Biopharma (CSCI) Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency Aug 27, 2024 07:30AM